The study demonstrates that thromboxane A2 is not essential for all forms of platelet activation, challenging the traditional concept of its obligate role in aggregation.
Answers are grounded in this paper and cite their sources.
Challenges thromboxane A2's obligate role in aggregation in this animal model; leaves open human relevance and should not alter practice.
The behaviour of human platelets was studied by mechanical induced platelet aggregation under inhibition of different enzymes of the arachidonic acid metabolism. Platelet aggregation was followed by the release of thromboxane B2 (TXB2) and prostaglandin E2 (PGE2). The cyclooxygenase inhibitor indomethacin suppressed the generation of both arachidonic acid metabolites simultaneously with the platelet aggregation. Imidazole or OKY-1581 inhibited the aggregation induced synthesis of TXB2 in a dose dependent manner whereas the PGE2 synthesis increased. After selective inhibition of endogenous TXB2 generation by imidazole or OKY-158l no correlation was found between platelet aggregation and thromboxane synthesis in platelet rich plasma. These results are in contrast to the general concept that platelet aggregation is mediated by TXA2. It is concluded that TXA2 is not essential for all sorts of platelet activation.
No takes yet. Share an insight, caveat, or question.
Steinhauer et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: